Policy | July 11, 2025
EU launches strategies to strengthen crisis readiness and health security
The Medical Countermeasures Strategy focuses on strengthening the EU’s preparedness for health crises
The Medical Countermeasures Strategy focuses on strengthening the EU’s preparedness for health crises
These medicines are essential in preventing RhD immunisation during pregnancy
Vevzuo is authorized for the prevention of skeletal related events in adults with advanced malignancies involving bone
Approval based on NIAGARA Phase III trial results which showed a 32% reduction in the risk of recurrence and a 25% reduction in the risk of death for the Imfinzi regimen vs. neoadjuvant chemotherapy alone
AMPLIFY Phase III trial results demonstrated statistically significant and clinically meaningful improvement in progression-free survival for Calquence combinations
YESINTEK is indicated for the treatment of adults and children from the age of 6 years and olde
CuraTeQ Biologics receives approval for biosimilar Zefylti from UK’s MHRA
Phesgo label expansion delivers on patients’ preference for at-home administration and is an important step in freeing up cancer care capacity in clinical settings
The positive opinions are based on applications submitted by Biosimilar Collaborations Ireland Limited
Trastuzumab specifically binds and inhibits the human epidermal growth factor receptor 2 (HER2) protein
Subscribe To Our Newsletter & Stay Updated
